TITLE

Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial

AUTHOR(S)
Schwartz, M. P.; Wellink, H.; Gooszen, H. G.; Conchillo, J. M.; Samsom, M.; Smout, A. J. P. M.
PUB. DATE
January 2007
SOURCE
Gut;Jan2007, Vol. 56 Issue 1, p20
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Endoscopic treatment for gastro-oesophageal reflux disease (GORD) is rapidly emerging, but there is a great need for randomised controlled trials to evaluate the efficacy. Design and setting: A single-centre, double-blind, randomised, sham-controlled trial of endoscopic gastroplication by the Endocinch suturing system. Patients and interventions: 60 patients with GORD were randomly assigned to three endoscopic gastroplications (n 20), a sham procedure (n = 20) or observation (n = 20). The research nurse and patients in the active and sham groups were blinded to the procedure assignment. After 3 months, open-label active treatment was offered to all patients. Outcome measures: The primary outcome measures were proton pump inhibitor (PPI) use and GORD symptoms, and secondary measures were quality of life, 24-h oesophageal acid exposure, oesophageal manometry and adverse events. Follow-up assessments were performed at 3, 6 and 12 months. Results: At 3 months, the percentage of patients who had reduced drug use by ⩾50% was greater in the active treatment group (65%) than in the sham (25%) or observation groups (0%) (p<0.02). Symptoms (heartburn and to a lesser extent regurgitation) improved more in the active group than in the sham group. Three Short Form-20 quality of life subscales (role function, general health and bodily pain perception) improved in the active group versus sham. Oesophageal acid exposure was modestly decreased after active treatment (p<0.02), but not significantly greater than after the sham procedure (p=0.61). The active treatment effects on PPI use, symptoms and quality of life persisted after 6 and 12 months of open-label follow-up (n =41), but 29% of patients were retreated in this period. No serious adverse events occurred. Conclusions: Endoscopic gastroplication, using the Endocinch device, reduced acid-inhibitory drug use, improved GORD symptoms and improved the quality of life at 3 months compared with a sham procedure. The effects persisted up to 12 months. However, the reduction in oesophageal acid exposure was not greater after endoscopic treatment than after a sham procedure.
ACCESSION #
23627616

 

Related Articles

  • Refractory Gastro-Oesophageal Reflux Disease. Liu, Julia J.; Saltzman, John R. // Drugs;2009, Vol. 69 Issue 14, p1935 

    Refractory gastro-oesophageal reflux disease (GORD) is described when reflux symptoms have not responded to 4-8 weeks of proton pump inhibitor therapy and occurs in a heterogeneous mixture of patients. The causes of refractory GORD include inadequate acid suppression, non-acid gastrooesophageal...

  • Effect of Mosapride Combined with Esomeprazole Improves Esophageal Peristaltic Function in Patients with Gastroesophageal Reflux Disease: A Study Using High Resolution Manometry. Cho, Yu; Choi, Myung-Gyu; Park, Eun; Lim, Chul; Kim, Jin; Park, Jae; Lee, In; Kim, Sang; Choi, Kyu // Digestive Diseases & Sciences;Apr2013, Vol. 58 Issue 4, p1035 

    Background: Whether addition of prokinetics to proton pump inhibitors improves esophageal peristalsis and symptoms in patients with gastroesophageal reflux disease (GERD) remains unknown. Aim: We evaluated the effect of mosapride, a 5-HT agonist, and PPI cotherapy in patients with GERD on...

  • Efficacy of Drugs Used in Gastro-Oesophageal Reflux: Network Meta-Analysis. Bolaños-Díaz, Rafael; Velarde-Criado, Héctor; Cóndor-Mori, Erik // Pharmacology & Pharmacy;Apr2013, Vol. 4 Issue 2, p201 

    Introduction: It is important to rank the clinical efficacy of different anti-reflux agents to promote their rational use. Objective: To combine the results of randomized clinical trials that have compared the incidence of symptoms related to gastro-oesophageal reflux (GER) with/without...

  • Yield of 24-Hour Esophageal pH and Bilitec Monitoring in Patients with Persisting Symptoms on PPI Therapy. George Karamanolis; Tim Vanuytsel; Daniel Sifrim; Raf Bisschops; Joris Arts; Philip Caenepeel; Dominiek Dewulf // Digestive Diseases & Sciences;Sep2008, Vol. 53 Issue 9, p2387 

    Abstract  Current management algorithms propose pH monitoring under proton pump inhibitors (PPIs) in suspected gastroesophageal reflux disease (GERD) with insufficient treatment response, but recent observations challenge this approach because of its low yield. Aim To perform an audit of...

  • Current Understanding of the Mechanisms of Gastro-oesophageal Reflux Disease. Orlando, Roy C. // Drugs;2006 Supplement 1, Vol. 66, p1 

    Gastro-oesophageal reflux disease (GERD) covers a broad range of signs and symptoms arising from the orad movement of gastric contents into the oesophagus, oropharynx, larynx or airway. Most commonly, contact with and damage to the oesophageal epithelium by acidic refluxate causes micro or...

  • Non-erosive Reflux Disease and Atypical Gastro-oesophageal Reflux Disease Manifestations: Treatment Results. Galmiche, Jean Paul // Drugs;2006 Supplement 1, Vol. 66, p7 

    Gastro-oesophageal reflux disease (GERD) is a widespread complex disorder that may be responsible for a variety of different symptoms and clinical features. Despite the presence of symptoms, the majority of patients do not have endoscopic lesions of oesophagitis. Non-erosive reflux disease...

  • Laryngitis and Gastroesophageal Reflux Disease: Increasing Prevalence or Poor Diagnostic Tests? Vaezi, Michael F. // American Journal of Gastroenterology;May2004, Vol. 99 Issue 5, p786 

    Laryngeal signs and symptoms are often associated with gastroesophageal reflux disease (GERD). However, such diagnoses presume that laryngeal findings may be specific for GERD. However, neither laryngoscopy, EGD or pH monitoring are specific tests for identifying GERD related laryngitis....

  • Managing Chronic Gastroesophageal Reflux Disease. Seehusen, Dean A.; Escano, Jude // American Family Physician;10/1/2012, Vol. 86 Issue 7, p617 

    The article explores the treatment of gastroesophageal reflux disease (GERD) in adults. It discusses the effectiveness of proton pump inhibitors (PPIs) in treating people with GERD. It defines GERD as the presence of chronic symptoms from abnormal reflux of stomach contents into the esophagus of...

  • DOES ENDOSCOPY ALTER MANAGEMENT FOR SIMPLE REFLUX DISEASE. Turner, G. B.; Tham, T. C. K. // Gut;Apr2004 Supplement 3, Vol. 53, pA10 

    The role of endoscopy for patients with simple gastro-oesophogeal reflux disease is unclear particularly under the age of 55 years. Authors report the influence of endoscopy on the management of 100 patients with uncomplicated reflux symptoms. Endoscopy for simple reflux symptoms led to a change...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics